Leptin and cardiovascular diseases

Clinical and Experimental Pharmacology and Physiology

Volumn 38, Issue 12, 2011, Pages 905-913

  Hou, Ning ^a   Luo, Jian Dong ^a  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Cardiovascular disease; Leptin; Obesity

Indexed keywords

ADIPOCYTOKINE; ANGIOTENSIN II; ATRASENTAN; BINDING PROTEIN; ENDOTHELIN 1; FATTY ACID; GROWTH FACTOR RECEPTOR BINDING PROTEIN 2; GW 6471; INSULIN RECEPTOR SUBSTRATE; INTERLEUKIN 6; JANUS KINASE; JANUS KINASE 2; LEPTIN; LEPTIN RECEPTOR; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ANTAGONIST; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN TYROSINE PHOSPHATASE 1B; PROTEIN TYROSINE PHOSPHATASE SHP 2; REACTIVE OXYGEN METABOLITE; STAT PROTEIN; STAT3 PROTEIN; STAT5 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3; TISSUE INHIBITOR OF METALLOPROTEINASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR;

ATHEROGENESIS; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM; CELL PROLIFERATION; ENDOTHELIAL DYSFUNCTION; EXTRACELLULAR MATRIX; FATTY ACID METABOLISM; FATTY ACID OXIDATION; HEART HYPERTROPHY; HEART MUSCLE CELL; HEART MUSCLE METABOLISM; HORMONE RESISTANCE; HUMAN; HYPERTENSION; IMMUNE RESPONSE; ISCHEMIC HEART DISEASE; LEPTIN RESISTANCE; LIPID STORAGE; NONHUMAN; OBESITY; OXIDATIVE STRESS; REVIEW; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; SYMPATHETIC TONE; THROMBOGENESIS; VASCULITIS;

EID: 82155180640     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2011.05619.x     Document Type: Review

References (80)

1. Wallace AM, McMahon AD, Packard CJ et al. Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation 2001; 104: 3052-6.
2. Despres JP. Intra-abdominal obesity: An untreated risk factor for Type 2 diabetes and cardiovascular disease. J. Endocrinol. Invest. 2006; 29: 77-82.
3. Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature 2006; 444: 875-80.
4. Wang MY, Zhou YT, Newgard CB, Unger RH. A novel leptin receptor isoform in rat. FEBS Lett. 1996; 392: 87-90.
5. Tartaglia LA. The leptin receptor. J. Biol. Chem. 1997; 272: 6093-6.
6. Yang R, Barouch LA. Leptin signaling and obesity: Cardiovascular consequences. Circ. Res. 2007; 101: 545-59.
7. Myers MG Jr. Leptin receptor signaling and the regulation of mammalian physiology. Recent Prog. Horm. Res. 2004; 59: 287-304.
8. Belin de Chantemele EJ, Muta K, Mintz J et al. Protein tyrosine phosphatase 1B, a major regulator of leptin-mediated control of cardiovascular function. Circulation 2009; 120: 753-63.
9. Bates SH, Stearns WH, Dundon TA et al. STAT3 signalling is required for leptin regulation of energy balance but not reproduction. Nature 2003; 421: 856-9.
10. Munzberg H, Bjornholm M, Bates SH, Myers MG Jr. Leptin receptor action and mechanisms of leptin resistance. Cell. Mol. Life Sci. 2005; 62: 642-52.
11. Tajmir P, Ceddia RB, Li RK, Coe IR, Sweeney G. Leptin increases cardiomyocyte hyperplasia via extracellular signal-regulated kinase- and phosphatidylinositol 3-kinase-dependent signaling pathways. Endocrinology 2004; 145: 1550-5.
12. Zeidan A, Javadov S, Chakrabarti S, Karmazyn M. Leptin-induced cardiomyocyte hypertrophy involves selective caveolae and RhoA/ROCK-dependent p38 MAPK translocation to nuclei. Cardiovasc. Res. 2008; 77: 64-72.
13. Hekerman P, Zeidler J, Bamberg-Lemper S et al. Pleiotropy of leptin receptor signalling is defined by distinct roles of the intracellular tyrosines. FEBS J. 2005; 272: 109-19.
14. Rahmouni K, Sigmund CD, Haynes WG, Mark AL. Hypothalamic ERK mediates the anorectic and thermogenic sympathetic effects of leptin. Diabetes 2009; 58: 536-42.
15. Morgan DA, Thedens DR, Weiss R, Rahmouni K. Mechanisms mediating renal sympathetic activation to leptin in obesity. Am. J. Physiol. Regul. Integ. Comp. Physiol. 2008; 295: R1730-6.
16. Wilsey J, Scarpace PJ. Caloric restriction reverses the deficits in leptin receptor protein and leptin signaling capacity associated with diet-induced obesity: Role of leptin in the regulation of hypothalamic long-form leptin receptor expression. J. Endocrinol. 2004; 181: 297-306.
17. Briancon N, McNay DE, Maratos-Flier E, Flier JS. Combined neural inactivation of suppressor of cytokine signaling-3 and protein-tyrosine phosphatase-1B reveals additive, synergistic, and factor-specific roles in the regulation of body energy balance. Diabetes 2010; 59: 3074-84.
18. Chen K, Li F, Li J et al. Induction of leptin resistance through direct interaction of C-reactive protein with leptin. Nat. Med. 2006; 12: 425-32.
19. Singh P, Hoffmann M, Wolk R, Shamsuzzaman AS, Somers VK. Leptin induces C-reactive protein expression in vascular endothelial cells. Arterioscler. Thromb. Vasc. Biol. 2007; 27: e302-7.
20. Romero-Corral A, Sierra-Johnson J, Lopez-Jimenez F et al. Relationships between leptin and C-reactive protein with cardiovascular disease in the adult general population. Nat. Clin. Pract. Cardiovasc Med. 2008; 5: 418-25.
21. Herder C, Baumert J, Zierer A et al. Immunological and Cardiometabolic Risk Factors in the Prediction of Type 2 Diabetes and Coronary Events: MONICA/KORA Augsburg Case-Cohort Study. PLoS One 2011; 6: e19852.
22. Gertler A, Niv-Spector L, Reicher S. Is leptin an important physiological regulator of CRP? Nat. Med. 2007; 13: author reply 18-9.
23. Abe Y, Ono K, Kawamura T et al. Leptin induces elongation of cardiac myocytes and causes eccentric left ventricular dilatation with compensation. Am. J. Physiol. Heart Circ. Physiol. 2007; 292: H2387-96.
24. Welsh P, Murray HM, Buckley BM et al. Leptin predicts diabetes but not cardiovascular disease: Results from a large prospective study in an elderly population. Diabetes Care 2009; 32: 308-10.
25. Liu J, Butler KR, Buxbaum SG, Sung JH, Campbell BW, Taylor HA. Leptinemia and its association with stroke and coronary heart disease in the Jackson Heart Study. Clin. Endocrinol. (Oxf). 2010; 72: 32-7.
26. Wannamethee SG, Tchernova J, Whincup P et al. Plasma leptin: Associations with metabolic, inflammatory and haemostatic risk factors for cardiovascular disease. Atherosclerosis 2007; 191: 418-26.
27. Sierra-Johnson J, Romero-Corral A, Lopez-Jimenez F et al. Relation of increased leptin concentrations to history of myocardial infarction and stroke in the United States population. Am. J. Cardiol. 2007; 100: 234-9.
28. Reilly MP, Iqbal N, Schutta M et al. Plasma leptin levels are associated with coronary atherosclerosis in type 2 diabetes. J. Clin. Endocrinol. Metab. 2004; 89: 3872-8.
29. Wallerstedt SM, Eriksson AL, Niklason A, Ohlsson C, Hedner T. Serum leptin and myocardial infarction in hypertension. Blood Press. 2004; 13: 243-6.
30. Brennan AM, Li TY, Kelesidis I, Gavrila A, Hu FB, Mantzoros CS. Circulating leptin levels are not associated with cardiovascular morbidity and mortality in women with diabetes: A prospective cohort study. Diabetologia 2007; 50: 1178-85.
31. Thogersen AM, Soderberg S, Jansson JH et al. Interactions between fibrinolysis, lipoproteins and leptin related to a first myocardial infarction. Eur. J. Cardiovasc Prev Rehabil. 2004; 11: 33-40.
32. McGaffin KR, Sun CK, Rager JJ et al. Leptin signalling reduces the severity of cardiac dysfunction and remodelling after chronic ischaemic injury. Cardiovasc. Res. 2008; 77: 54-63.
33. Lieb W, Sullivan LM, Aragam J et al. Relation of serum leptin with cardiac mass and left atrial dimension in individuals >70years of age. Am. J. Cardiol. 2009; 104: 602-5.
34. Rahmouni K, Correia ML, Haynes WG, Mark AL. Obesity-associated hypertension: New insights into mechanisms. Hypertension 2005; 45: 9-14.
35. Dubinion JH, da Silva AA, Hall JE. Chronic blood pressure and appetite responses to central leptin infusion in rats fed a high fat diet. J. Hypertens. 2011; 29: 758-62.
36. Carlyle M, Jones OB, Kuo JJ, Hall JE. Chronic cardiovascular and renal actions of leptin: Role of adrenergic activity. Hypertension 2002; 39: 496-501.
37. Rahmouni K, Morgan DA, Morgan GM, Mark AL, Haynes WG. Role of selective leptin resistance in diet-induced obesity hypertension. Diabetes 2005; 54: 2012-8.
38. Trevenzoli IH, Pinheiro CR, Conceicao EP et al. Programming of rat adrenal medulla by neonatal hyperleptinemia: Adrenal morphology, catecholamine secretion, and leptin signaling pathway. Am. J. Physiol. Endocrinol. Metab. 2010; 298: E941-9.
39. Rahmouni K, Morgan DA. Hypothalamic arcuate nucleus mediates the sympathetic and arterial pressure responses to leptin. Hypertension 2007; 49: 647-52.
40. Harlan SM, Morgan DA, Agassandian K et al. Ablation of the leptin receptor in the hypothalamic arcuate nucleus abrogates leptin-induced sympathetic activation. Circ. Res. 2011; 108: 808-12.
41. Kuo JJ, Jones OB, Hall JE. Inhibition of NO synthesis enhances chronic cardiovascular and renal actions of leptin. Hypertension 2001; 37: 670-6.
42. Rodriguez A, Fortuno A, Gomez-Ambrosi J, Zalba G, Diez J, Fruhbeck G. The inhibitory effect of leptin on angiotensin II-induced vasoconstriction in vascular smooth muscle cells is mediated via a nitric oxide-dependent mechanism. Endocrinology 2007; 148: 324-31.
43. McMahon M, Skaggs BJ, Sahakian L et al. High plasma leptin levels confer increased risk of atherosclerosis in women with systemic lupus erythematosus, and are associated with inflammatory oxidised lipids. Ann. Rheum. Dis. 2011; 70: 1619-24.
44. Beltowski J, Wojcicka G, Jamroz A. Leptin decreases plasma paraoxonase 1 (PON1) activity and induces oxidative stress: The possible novel mechanism for proatherogenic effect of chronic hyperleptinemia. Atherosclerosis 2003; 170: 21-9.
45. Korda M, Kubant R, Patton S, Malinski T. Leptin-induced endothelial dysfunction in obesity. Am. J. Physiol. Heart Circ. Physiol. 2008; 295: H1514-21.
46. Dubey L, Hesong Z. Role of leptin in atherogenesis. Exp. Clin. Cardiol. 2006; 11: 269-75.
47. Martin SS, Qasim A, Reilly MP. Leptin resistance: A possible interface of inflammation and metabolism in obesity-related cardiovascular disease. J. Am. Coll. Cardiol. 2008; 52: 1201-10.
48. Schafer K, Halle M, Goeschen C et al. Leptin promotes vascular remodeling and neointimal growth in mice. Arterioscler. Thromb. Vasc. Biol. 2004; 24: 112-7.
49. Li L, Mamputu JC, Wiernsperger N, Renier G. Signaling pathways involved in human vascular smooth muscle cell proliferation and matrix metalloproteinase-2 expression induced by leptin: Inhibitory effect of metformin. Diabetes 2005; 54: 2227-34.
50. Correia ML, Rahmouni K. Role of leptin in the cardiovascular and endocrine complications of metabolic syndrome. Diabetes Obes Metab 2006; 8: 603-10.
51. Garonna E, Botham KM, Birdsey GM, Randi AM, Gonzalez-Perez RR, Wheeler-Jones CP. Vascular endothelial growth factor receptor-2 couples cyclo-oxygenase-2 with pro-angiogenic actions of leptin on human endothelial cells. PLoS One 2011; 6: e18823.
52. Singh P, Peterson TE, Sert-Kuniyoshi FH, Jensen MD, Somers VK. Leptin upregulates caveolin-1 expression: Implications for development of atherosclerosis. Atherosclerosis 2010; 217: 499-502.
53. Bodary PF. Links between adipose tissue and thrombosis in the mouse. Arterioscler. Thromb. Vasc. Biol. 2007; 27: 2284-91.
54. Konstantinides S, Schafer K, Koschnick S, Loskutoff DJ. Leptin-dependent platelet aggregation and arterial thrombosis suggests a mechanism for atherothrombotic disease in obesity. J. Clin. Invest. 2001; 108: 1533-40.
55. Konstantinides S, Schafer K, Neels JG, Dellas C, Loskutoff DJ. Inhibition of endogenous leptin protects mice from arterial and venous thrombosis. Arterioscler. Thromb. Vasc. Biol. 2004; 24: 2196-201.
56. Dellas C, Schafer K, Rohm IK et al. Leptin signalling and leptin-mediated activation of human platelets: Importance of JAK2 and the phospholipases Cgamma2 and A2. Thromb. Haemost. 2007; 98: 1063-71.
57. Dellas C, Schafer K, Rohm I et al. Absence of leptin resistance in platelets from morbidly obese individuals may contribute to the increased thrombosis risk in obesity. Thromb. Haemost. 2008; 100: 1123-9.
58. Cirillo P, Angri V, De Rosa S et al. Pro-atherothrombotic effects of leptin in human coronary endothelial cells. Thromb. Haemost. 2010; 103: 1065-75.
59. Rajapurohitam V, Javadov S, Purdham DM, Kirshenbaum LA, Karmazyn M. An autocrine role for leptin in mediating the cardiomyocyte hypertrophic effects of angiotensin II and endothelin-1. J. Mol. Cell. Cardiol. 2006; 41: 265-74.
60. Xu FP, Chen MS, Wang YZ et al. Leptin induces hypertrophy via endothelin-1-reactive oxygen species pathway in cultured neonatal rat cardiomyocytes. Circulation 2004; 110: 1269-75.
61. Zeidan A, Hunter JC, Javadov S, Karmazyn M. MTOR mediates RhoA-dependent leptin-induced cardiomyocyte hypertrophy. Mol. Cell. Biochem. 2011; 352: 99-108.
62. Rajapurohitam V, Gan XT, Kirshenbaum LA, Karmazyn M. The obesity-associated peptide leptin induces hypertrophy in neonatal rat ventricular myocytes. Circ. Res. 2003; 93: 277-9.
63. Madani S, De Girolamo S, Munoz DM, Li RK, Sweeney G. Direct effects of leptin on size and extracellular matrix components of human pediatric ventricular myocytes. Cardiovasc. Res. 2006; 69: 716-25.
64. Luo JD, Xie F, Zhang WW, Ma XD, Guan JX, Chen X. Simvastatin inhibits noradrenaline-induced hypertrophy of cultured neonatal rat cardiomyocytes. Br. J. Pharmacol. 2001; 132: 159-64.
65. Hou N, Luo MS, Liu SM et al. Leptin induces hypertrophy through activating the peroxisome proliferator-activated receptor alpha pathway in cultured neonatal rat cardiomyocytes. Clin. Exp. Pharmacol. Physiol. 2010; 37: 1087-95.
66. Finck BN, Lehman JJ, Leone TC et al. The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. J. Clin. Invest. 2002; 109: 121-30.
67. Zeidan A, Javadov S, Karmazyn M. Essential role of Rho/ROCK-dependent processes and actin dynamics in mediating leptin-induced hypertrophy in rat neonatal ventricular myocytes. Cardiovasc. Res. 2006; 72: 101-11.
68. Barouch LA, Cappola TP, Harrison RW et al. Combined loss of neuronal and endothelial nitric oxide synthase causes premature mortality and age-related hypertrophic cardiac remodeling in mice. J. Mol. Cell. Cardiol. 2003; 35: 637-44.
69. Sweeney G. Cardiovascular effects of leptin. Nat. Rev. Cardiol. 2010; 7: 22-9.
70. Zaman AK, Fujii S, Goto D et al. Salutary effects of attenuation of angiotensin II on coronary perivascular fibrosis associated with insulin resistance and obesity. J. Mol. Cell. Cardiol. 2004; 37: 525-35.
71. Leopoldo AS, Sugizaki MM, Lima-Leopoldo AP et al. Cardiac remodeling in a rat model of diet-induced obesity. Can. J. Cardiol. 2010; 26: 423-9.
72. Schram K, Wong MM, Palanivel R, No EK, Dixon IM, Sweeney G. Increased expression and cell surface localization of MT1-MMP plays a role in stimulation of MMP-2 activity by leptin in neonatal rat cardiac myofibroblasts. J. Mol. Cell. Cardiol. 2008; 44: 874-81.
73. Abel ED, Litwin SE, Sweeney G. Cardiac remodeling in obesity. Physiol. Rev. 2008; 88: 389-419.
74. Atkinson LL, Fischer MA, Lopaschuk GD. Leptin activates cardiac fatty acid oxidation independent of changes in the AMP-activated protein kinase-acetyl-CoA carboxylase-malonyl-CoA axis. J. Biol. Chem. 2002; 277: 29424-30.
75. Sharma V, Mustafa S, Patel N, Wambolt R, Allard MF, McNeill JH. Stimulation of cardiac fatty acid oxidation by leptin is mediated by a nitric oxide-p38 MAPK-dependent mechanism. Eur. J. Pharmacol. 2009; 617: 113-7.
76. Palanivel R, Eguchi M, Shuralyova I, Coe I, Sweeney G. Distinct effects of short- and long-term leptin treatment on glucose and fatty acid uptake and metabolism in HL-1 cardiomyocytes. Metabolism 2006; 55: 1067-75.
77. Sharma S, Adrogue JV, Golfman L et al. Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart. FASEB J. 2004; 18: 1692-700.
78. Murphy S, Frishman WH. Protein kinase C in cardiac disease and as a potential therapeutic target. Cardiol. Rev. 2005; 13: 3-12.
79. Haap M, Houdali B, Maerker E et al. Insulin-like effect of low-dose leptin on glucose transport in Langendorff rat hearts. Exp. Clin. Endocrinol. Diabetes 2003; 111: 139-45.
80. Wang P, Lloyd SG, Zeng H, Bonen A, Chatham JC. Impact of altered substrate utilization on cardiac function in isolated hearts from Zucker diabetic fatty rats. Am. J. Physiol. Heart Circ. Physiol. 2005; 288: H2102-10.